CHLORAPREP SINGLE SWABSTICK Drug Patent Profile

Which patents cover Chloraprep Single Swabstick, and what generic alternatives are available?

Chloraprep Single Swabstick is a drug marketed by Becton Dickinson Co and is included in one NDA.

The generic ingredient in CHLORAPREP SINGLE SWABSTICK is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Summary for CHLORAPREP SINGLE SWABSTICK

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
DailyMed Link:	CHLORAPREP SINGLE SWABSTICK at DailyMed

Recent Clinical Trials for CHLORAPREP SINGLE SWABSTICK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CareFusion	Phase 3

See all CHLORAPREP SINGLE SWABSTICK clinical trials

Pharmacology for CHLORAPREP SINGLE SWABSTICK

Physiological Effect

Decreased Cell Wall Integrity

US Patents and Regulatory Information for CHLORAPREP SINGLE SWABSTICK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Becton Dickinson Co	CHLORAPREP SINGLE SWABSTICK	chlorhexidine gluconate; isopropyl alcohol	SWAB;TOPICAL	021555-002	May 10, 2005		OTC	Yes	Yes

Expired US Patents for CHLORAPREP SINGLE SWABSTICK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Becton Dickinson Co	CHLORAPREP SINGLE SWABSTICK	chlorhexidine gluconate; isopropyl alcohol	SWAB;TOPICAL	021555-002	May 10, 2005

International Patents for CHLORAPREP SINGLE SWABSTICK

See the table below for patents covering CHLORAPREP SINGLE SWABSTICK around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2000507478
World Intellectual Property Organization (WIPO)	9814178
Russian Federation	2200532	DOSAGE APPLICATOR OF BACTERICIDAL SUBSTANCE AND METHOD FOR ITS MANUFACTURING

Market Dynamics and Financial Trajectory for Chloraprep Single Swabstick

Last updated: February 24, 2026

Chloraprep Single Swabstick (Chlorhexidine gluconate 2% and isopropyl alcohol 70%) is a topical antiseptic used primarily for skin disinfection prior to surgery or invasive procedures. Its market is influenced by regulatory approvals, competitive landscape, safety profile, and healthcare infrastructure.

Market Overview

The global antiseptic market, valued at approximately $7.8 billion in 2022, is projected to reach $10.4 billion by 2030, growing at a CAGR of around 3.4%, driven by increased demand for infection prevention, expanding surgical procedures, and rising awareness of hygiene.

Within this market, Chloraprep holds a significant share, especially in surgical site disinfection. It competes with alcohol swabs, povidone-iodine, and other chlorhexidine-based products.

Key Market Drivers and Restraints

Drivers

• Growing surgical volume: An estimated 310 million surgeries worldwide occur annually, increasing demand for preoperative skin antiseptics.
• Infection control policies: Hospitals' focus on reducing healthcare-associated infections (HAIs) supports antiseptic product sales.
• Regulatory approvals: Approval expansions and updated guidelines bolster market acceptance.

Restraints

• Price sensitivity: Swabstick products are subject to procurement negotiations, influencing sales volumes.
• Safety concerns: Rare allergic reactions to chlorhexidine may limit use in certain populations.
• Alternative products: Increased adoption of alcohol wipes and povidone-iodine reduces market share growth prospects.

Regulatory and Reimbursement Landscape

• FDA approval ensures product safety and efficacy in the U.S..
• European CE marking facilitates access in the EU.
• Reimbursement policies generally favor antiseptic products in hospital settings, with prices negotiated by healthcare providers and insurers.

Competitive Landscape

Company	Key Product Variants	Market Share (est.)	Entry Barriers
3M Healthcare	Chloraprep, povidone-iodine	~40%	Regulatory, distribution
Iodoflex	Iodine-based antiseptics	~15%	Brand recognition
Other regional players	Various chlorhexidine products	20%	Regulatory approval

Financial Trajectory

Revenue Estimates

• Current sales of Chloraprep in the U.S. exceed $400 million annually.
• Growth projections suggest a CAGR of 2-4% over the next five years, aligning with hospital procurement trends.
• Regional expansion in Asia-Pacific and Latin America, driven by increased healthcare infrastructure, could boost revenues by 10-15% annually.

Price and Volume Dynamics

• Average wholesale price per swabstick ranges between $1.50 and $2.00.
• Volume sales are driven by hospital procurement cycles, typically 6-12 months.
• Price pressures from large hospital systems and group purchasing organizations (GPOs) constrain profit margins.

Investment and R&D Outlook

Manufacturers invest in developing combination formulations and new delivery systems. Incremental innovations aim to improve skin adhesion, reduce allergic reactions, and extend shelf life.

Key Risks and Opportunities

Risks

• Regulatory changes or recalls affecting safety profiles.
• Emerging counterfeit or inferior products reducing brand reputation.
• Competitive pricing pressures from generics or private-label products.

Opportunities

• Introducing single-use prefilled antiseptic devices.
• Expanding product lines into outpatient and ambulatory surgery centers.
• Developing formulations targeting pediatric and allergenic populations.

Summary Table of Financial Indicators

Indicator	2022 Actual	Forecast 2028
U.S. sales volume (million units)	210 million	250 million
Average selling price per unit	$1.75	$1.60
Estimated global revenue	$350 million	$410 million
CAGR over 2023-2028	3%

Conclusion

The market for Chloraprep Single Swabstick remains stable with moderate growth prospects tied to increased surgical volume and infection control policies. Competition and pricing pressures persist, but regional expansion and incremental innovation provide avenues for revenue growth.

---

Key Takeaways

• The global antiseptic market is expected to grow at a CAGR of 3.4%, with robust demand for surgical antiseptics like Chloraprep.
• Current U.S. sales exceed $400 million per year, with future growth driven by hospital procurement and regional expansion.
• Price sensitivity and safety concerns limit aggressive market expansion, but innovation and differentiation offer growth opportunities.
• Competitive landscape dominated by 3M Healthcare, with regional players maintaining niche shares.
• Strategic focus on outpatient market segments and new formulation development can enhance revenue streams.

---

FAQs

1. What factors influence the pricing of Chloraprep Swabsticks?
   Pricing is affected by hospital procurement contracts, GPO negotiations, manufacturing costs, and competitive pressures.

2. What are the main safety concerns associated with Chloraprep?
   Possible allergic reactions, skin irritation, and rare cases of chlorhexidine toxicity can restrict use in vulnerable populations.

3. How does the regulatory environment impact Chloraprep sales?
   Regulatory approvals facilitate market access; delays or recalls can restrict sales and affect brand reputation.

4. What are the primary substitutes for Chloraprep?
   Alcohol wipes, povidone-iodine products, and other chlorhexidine formulations.

5. What strategic moves are companies making to grow their share in this market?
   Innovation in delivery systems, geographic expansion, and targeting outpatient settings.

---

References

1. Grand View Research. (2023). Antiseptic and Disinfectant Market Size, Share & Trends Analysis Report.
2. IQVIA. (2022). Global Surgical Procedures Report.
3. U.S. Food and Drug Administration. (2022). Medical Device Approvals Database.
4. European Medicines Agency. (2023). Medical Device Regulation Updates.
5. Statista. (2022). Healthcare-Associated Infection (HAI) Market Data.